NASDAQ · BLUE
Healthcare · Biotechnology
$4.97
Up+$0.00 (+0.00%)
Updated Aug 14, 2026, 4:50 PM
SID Score
—
Composite research score
Smart Money
—
Institutional and insider signal
Price performance
1M range · 0 trading sessions · Daily adjusted prices
BLUE does not have enough price history for the selected period.
Data unavailable
The requested market data was not found.
The latest Smart Investors Daily articles mentioning BLUE.
BLUE research
Company profile and research snapshot.
bluebird bio, Inc., a biotechnology company, researches, develops, and commercializes transformative gene therapies for severe genetic diseases. Its product candidates for severe genetic diseases include betibeglogene autotemcel for the treatment of transfusion-dependent ß-thalassemia; lovotibeglogene autotemcel for the treatment of sickle cell disease (SCD); and elivaldogene autotemcel to treat cerebral adrenoleukodystrophy. The company's clinical study program includes HGB-205, HGB-206, and HGB-210 to evaluate the safety and efficacy of lovo-cel in the treatment of patients with SCD; and HGB-204, HGB-205, HGB-207, and HGB-212 to evaluate the safety and efficacy of beti-cel in the treatment of patients with ß-thalassemia. It has strategic collaboration and license agreements with Orchard Therapeutics Limited, Forty Seven, Inc., and Magenta Therapeutics, Inc. The company was formerly known as Genetix Pharmaceuticals, Inc., and changed its name to bluebird bio, Inc. in September 2010. bluebird bio, Inc. was incorporated in 1992 and is headquartered in Cambridge, Massachusetts.
Visit company websiteConsensus and target data currently published for this company.
| Date | Firm | Rating | Target |
|---|---|---|---|
| Mar 31, 2025 | Barclays | Overweight | — |
| Feb 24, 2025 | Wells Fargo | Equal-Weight | — |
| Feb 24, 2025 | JP Morgan | Neutral | — |
| Dec 31, 2024 | Barclays | Overweight | — |
| Nov 15, 2024 | B of A Securities | Neutral | — |
No generated briefing is available yet.
prnewswire.com · Nov 30, 2025
Shareholders should contact the firm immediately as there may be limited time to enforce your rights. NEW YORK , Nov. 30, 2025 /PRNewswire/ -- Halper Sadeh LLC, an investor rights law firm, is investigating whether certain officers and directors of Blue Ridge Bankshares, Inc. (NYSEAMERICAN: BRBS) breached their fiduciary duties to shareholders.
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
The latest Smart Investors Daily articles mentioning BLUE.
No results
No recent SID articles mention BLUE.
